Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (91-100 of 184) with videos related to

Pageof 19
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 15, 2020
Approach to the Treatment of a Patient with an Aggressive Pituitary TumorAndrew L Lin, Mark T A Donoghue, Sharon L Wardlaw, et al.
Journal of Clinical Medicine|July 3, 2019
A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene MutationAgnieszka Kolasinska-Ćwikła, Mariola Pęczkowska, Jarosław B Ćwikła, et al.
European Journal of Endocrinology|August 14, 2014
GEPNETs update: Radionuclide therapy in neuroendocrine tumorsWouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2008
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.
Plos One|June 28, 2019
Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosisMark Kidd, Ignat A Drozdov, Somer Matar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2010
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumorsValentina Ambrosini, Davide Campana, Lisa Bodei, et al.
Annals of Surgical Oncology|September 11, 2016
Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver MetastasesEmilio Bertani, Nicola Fazio, Davide Radice, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2021
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future ProspectsSonya Park, Ashwin Singh Parihar, Lisa Bodei, et al.
Surgery|March 4, 2014
Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approachEmilio Bertani, Nicola Fazio, Edoardo Botteri, et al.
Pageof 19

Showing results (91-100 of 184) with videos related to

Sort By:
Pageof 19
The Journal of Clinical Endocrinology and Metabolism|September 15, 2020
Approach to the Treatment of a Patient with an Aggressive Pituitary TumorAndrew L Lin, Mark T A Donoghue, Sharon L Wardlaw, et al.
Journal of Clinical Medicine|July 3, 2019
A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene MutationAgnieszka Kolasinska-Ćwikła, Mariola Pęczkowska, Jarosław B Ćwikła, et al.
European Journal of Endocrinology|August 14, 2014
GEPNETs update: Radionuclide therapy in neuroendocrine tumorsWouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 23, 2008
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2003
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I studyLisa Bodei, Marta Cremonesi, Stefania Zoboli, et al.
Plos One|June 28, 2019
Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosisMark Kidd, Ignat A Drozdov, Somer Matar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2010
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumorsValentina Ambrosini, Davide Campana, Lisa Bodei, et al.
Annals of Surgical Oncology|September 11, 2016
Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver MetastasesEmilio Bertani, Nicola Fazio, Davide Radice, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2021
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future ProspectsSonya Park, Ashwin Singh Parihar, Lisa Bodei, et al.
Surgery|March 4, 2014
Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approachEmilio Bertani, Nicola Fazio, Edoardo Botteri, et al.
Pageof 19